It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Necrotizing enterocolitis (NEC) is a devastating disease of premature infants with high mortality rate, indicating the need for precision treatment. NEC is characterized by intestinal inflammation and ischemia, as well derangements in intestinal microcirculation. Remote ischemic conditioning (RIC) has emerged as a promising tool in protecting distant organs against ischemia-induced damage. However, the effectiveness of RIC against NEC is unknown. To address this gap, we aimed to determine the efficacy and mechanism of action of RIC in experimental NEC. NEC was induced in mouse pups between postnatal day (P) 5 and 9. RIC was applied through intermittent occlusion of hind limb blood flow. RIC, when administered in the early stages of disease progression, decreases intestinal injury and prolongs survival. The mechanism of action of RIC involves increasing intestinal perfusion through vasodilation mediated by nitric oxide and hydrogen sulfide. RIC is a viable and non-invasive treatment strategy for NEC.
Necrotizing enterocolitis (NEC) is one of the most lethal gastrointestinal emergencies in neonates needing precision treatment. Here the authors show that remote ischemic conditioning is a non-invasive therapeutic method that enhances blood flow in the intestine, reduces damage, and improves NEC outcome.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 The Hospital for Sick Children, Translational Medicine Program, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); The Hospital for Sick Children, Division of General and Thoracic Surgery, Translational Medicine, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); Mie University Graduate School of Medicine, Departments of Gastrointestinal and Pediatric Surgery, Tsu, Japan (GRID:grid.260026.0) (ISNI:0000 0004 0372 555X)
2 The Hospital for Sick Children, Translational Medicine Program, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); The Hospital for Sick Children, Division of General and Thoracic Surgery, Translational Medicine, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646)
3 The Hospital for Sick Children, Division of Neonatology, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646)
4 Hospital for Sick Children, Cell Biology Program, Research Institute, Division of Gastroenterology, Hepatology and Nutrition, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); University of Toronto, Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
5 Mie University Graduate School of Medicine, Departments of Gastrointestinal and Pediatric Surgery, Tsu, Japan (GRID:grid.260026.0) (ISNI:0000 0004 0372 555X)
6 The Hospital for Sick Children, Translational Medicine Program, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); University of Toronto, Department of Molecular Genetics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); Heart & Stroke Richard Lewar Centre of Excellence, Toronto, Canada (GRID:grid.423576.1)
7 University of Toronto, The Labatt Family Heart Center, Cardiology, The Hospital for Sick Children, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
8 University of Toronto, Department of Diagnostic Imaging, Division of Nuclear Medicine, The Hospital for Sick Children, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
9 UCL Great Ormond Street Institute of Child Health, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
10 Hospital for Sick Children, Cell Biology Program, Research Institute, Division of Gastroenterology, Hepatology and Nutrition, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); University of Toronto, Faculty of Dentistry, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
11 The Hospital for Sick Children, Translational Medicine Program, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); The Hospital for Sick Children, Division of General and Thoracic Surgery, Translational Medicine, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); University of Toronto, Department of Surgery, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)